The U.S. Food and Drug Administration (FDA) has approved Komzifti (ziftomenib), which is a type of treatment known as a menin ...
Ziftomenib (Komzifti; Kura Oncology and Kyowa Kirin), an oral, once-daily, selective menin inhibitor, has received approval from the FDA for the treatment of adult patients with relapsed or refractory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback